1. Introduction
===============

The pyrazolo\[1,5-*c*\]pyrimidine ring represents a biologically and synthetically important class of compounds. Many pyrazolo\[1,5-*c*\]pyrimidines are known to possess significant hypnotic, tranquilizing, fungicidal, insecticidal and antibacterial activities \[[@B1-molecules-16-07081],[@B2-molecules-16-07081],[@B3-molecules-16-07081]\]. Also, the coordination of pyrazolo\[1,5-*c*\]pyrimidines to transition metal ions such as Cu^+2^ and Ni^+2^ enhances their biological activities \[[@B4-molecules-16-07081],[@B5-molecules-16-07081],[@B6-molecules-16-07081],[@B7-molecules-16-07081]\].

In the last few decades, the chemistry of 1,2,4-triazoles and their fused heterocyclic derivatives has received considerable attention owing to their synthetic and effective biological importance. 1,2,4- Triazole moieties have been incorporated into a wide variety of therapeutically interesting drug candidates, e.g., triazolam \[[@B8-molecules-16-07081]\], alprazolam \[[@B9-molecules-16-07081]\], etizolam \[[@B10-molecules-16-07081]\], and furacylin \[[@B11-molecules-16-07081]\], including anti- inflammatories, central nervous system stimulants, sedatives, anti-anxiety compounds, antimicrobial agents \[[@B12-molecules-16-07081],[@B13-molecules-16-07081],[@B14-molecules-16-07081],[@B15-molecules-16-07081]\] and antimycotic ones such as fluconazole, intraconazole, voriconazole \[[@B16-molecules-16-07081],[@B17-molecules-16-07081]\].

The above mentioned therapeutic activity has prompted the present investigation to synthesize the pyrazolo\[1,5-*c*\]-1,2,4-triazolo\[4,3-*a*\]pyrimidines ring system **2** and a new series of 7-acetylhydrazino-5-aryl-2-phenylpyrazolo\[1,5-*c*\]pyrimidine derivatives **7**.

2. Results and Discussion
=========================

Much work from our laboratory has utilized hydrazino heterocycles as raw materials for the synthesis of various types of heterocyclic compounds \[[@B18-molecules-16-07081],[@B19-molecules-16-07081],[@B20-molecules-16-07081],[@B21-molecules-16-07081]\]. In the present investigation, the target pyrazolotriazolopyrimidine compounds were synthesized from 5-aryl-7-hydrazino-2-phenyl-pyrazolo\[1,5-*c*\]pyrimidines **1a-d** that were prepared via a sequence of reactions from ethyl phenylpropiolate \[[@B2-molecules-16-07081],[@B22-molecules-16-07081]\]. Heating of **1a-d** with formic acid under reflux yielded a novel series of 5-aryl-8-phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo\[4,3-*a*\]pyrimidines **2a-d** ([Scheme 1](#molecules-16-07081-f001){ref-type="scheme"}). The structures of **2a-d** were deduced from their spectral analyses. Thus, the ^1^H-NMR spectra revealed the presence of three singlets for the pyrazole ring proton at δ~H~ 6.91--7.33 ppm, of the pyrimidine ring proton at δ~H~ 7.43--7.44 ppm and of triazole ring proton at δ~H~ 8.53--9.00 ppm, in addition to the aromatic ring protons and the absence of NH signals. The MS spectra also showed a molecular ion peak as a base peak that indicated the stability of this ring.

The electrophilic substitution reactions of pyrazolotriazolopyrimidines **2a-d** such as bromination with bromine, iodination with iodine monochloride and nitration with nitric and sulfuric acids in glacial acetic acid gave the respective 5-aryl-6-bromo-, 5-aryl-6-iodo- and 5-aryl-6-nitro-8- phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo\[4,3-*a*\]pyrimidines **3a-d**, **4a-d** and **5a-d**. Their ^1^H-NMR spectra revealed the absence of signals due to the pyrimidine ring proton and the presence of a pyrazole ring proton signal at δ~H~ 6.81--7.33 ppm and a triazole ring proton singlet at δ~H~ 8.52--9.04 ppm, together with the aromatic proton signals at δ~H~ 7.12--8.14 ppm. The structure of these derivatives were also confirmed from their mass spectral data.

Treatment of **1a-d** with boiling ethyl formate afforded 5-aryl-7-formylhydrazino-2- phenylpyrazolo\[1,5-*c*\]pyrimidines **6a-d**. Their ^1^H-NMR spectra showed a new characteristic signal at δ~H~ 7.98--8.08 ppm corresponding to the formyl proton, in addition to the aromatic ring protons at δ~H~ 7.20--7.99 ppm, with other characteristic signals; a singlet for the exchangeable two NH protons which were assigned at δ~H~ 4.73--4.80 ppm, a singlet at δ~H~ 6.68--6.72 ppm for the pyrazole ring proton and a singlet at δ~H~ 7.19--7.29 ppm for the pyrimidine ring proton.

![Synthesisandelectrophilicsubstitutionreactionsofpyrazolotriazolopyrimidines.](molecules-16-07081-g001){#molecules-16-07081-f001}

Boiling of hydrazine derivatives **1a-d** with acetic acid under reflux afforded 7-acetylhydrazino-5- aryl-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **7a-d** ([Scheme 2](#molecules-16-07081-f002){ref-type="scheme"}). The structures of **7a-d** were confirmed by their ^1^H-NMR spectra, which revealed an acetyl group proton singlet at δ~H~ 2.04--2.36 ppm, in addition to the characteristic signals of pyrazole and pyrimidine ring protons, two exchangeable NH protons and aromatic ring protons. The mass spectra of **7a-d** which showed their molecular ion peaks as a base peak also confirmed the structures.

Next, the electrophilic substitution reaction of **7a-d** via bromination with bromine in acetic acid gave the unexpected dibromo derivatives **8a-d** rather than the monobromo derivatives. Their ^1^H-NMR spectra showed the absence of the signals of both pyrazole and pyrimidine ring protons and the presence of acetyl group protons, in addition to the other characteristic signals. These unexpected obtained products may be due to the excess bromine added to obtain a homogenous reaction mixture.

Iodination and nitration of **7a-d** yielded the expected 5-aryl-2-phenyl-3-substituted-pyrazolo\[1,5- *c*\]pyrimidine derivatives **9a-d** and **10a-d**, respectively . Their ^1^H-NMR spectra revealed the absence of pyrazole ring proton and the presence of pyrimidine ring proton at δ~H~7.18--7.73 ppm as well as the other characteristic signals.

![Synthesisandelectrophilicsubstitutionreactionsof7-acetyl-hydrazinopyrazolopyrimidines.](molecules-16-07081-g002){#molecules-16-07081-f002}

Furthermore, acetylation of **1a-d** with boiling acetic anhydride afforded the triacetyl derivatives **11a-d**. Their ^1^H-NMR spectra revealed the absence of the NH protons of the starting hydrazine derivatives and the presence of signals at δ~H~ 2.42--2.56 ppm corresponding to the three acetyl groups protons, as well as a singlet at δ~H~ 6.87--7.28 ppm for the pyrazole ring proton and a singlet at δ~H~ 7.70--8.24 ppm for the pyrimidine ring proton, in addition to the aromatic ring protons at δ~H~ 6.98--8.05 ppm. The structures of **11a-d** were also confirmed by their MS spectra which showed fragmentation process involving a sequential elimination of two ketene molecules to give the most stable one (M^.+^-2CH~2~CO) as a base peak.

3. Experimental
===============

3.1. General
------------

Melting points were determined on a Kofler Block and are uncorrected. Elemental analyses were carried out in the Microanalytical Laboratory of the Faculty of Science, Cairo University. The IR spectra of compounds were recorded on a Bruker Tensor 37 Fourier Transform infrared 8400 spectrophotometer using potassium bromide pellets and frequencies are reported in cm^−1^. The ^1^H- NMR spectra were recorded on a JEOL JNM ECA 500 MHZ instrument and chemical shifts δ~H~ are given in ppm relative to tetramethylsilane used as internal standard. Mass spectra were recorded at 70 ev with a GCMS-QP 1000 EX spectrometer. Reactions were routinely followed by thin layer chromatography (TLC; Merck Kieselgel60-F254 precoated plastic plates). The spots were detected by iodine. 5-Aryl-7-hydrazino-2- phenylpyrazolo\[1,5-*c*\]pyrimidines **1** were prepared from the respective acetylenic β-diketones as described earlier \[[@B2-molecules-16-07081],[@B22-molecules-16-07081]\].

3.2. Synthesis of Compounds
---------------------------

### 3.2.1. 5-Aryl-8-phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo\[4,3-*a*\]pyrimidines **2a-d**

A mixture of 5-aryl-7-hydrazino-2-phenylpyrazolo\[1,5-*c*\]pyrimidines (**1a-d**, 1 mmol) and formic acid (10 mL, 99%) was heated under reflux for 10 h. The mixture was evaporated under reduced pressure and the obtained residue was triturated with water, filtered, washed with EtOH and crystallized from EtOH to give the 5-aryl-8-phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo\[4,3-*a*\]pyrimidines **2a-d** as colorless needles.

*5,8-Diphenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**2a**). Yield 81%, 0.25 g, mp 245--246 °C; IR (υ~max~, cm^−1^): 1649 (pyrazole ring C=N), 1580 (triazole ring C=N), and 1476 (C=C); ^1^H-NMR (CDCl~3~, δ~H~, ppm): 6.91 (s, 1H, pyrazole-H), 7.43 (s, 1H, pyrimidine-H), 7.45--7.64 (m, 8H, aromatic- H), 8.05 (d, 2H, aromatic-H) and 8.53 (s, 1H, triazole-H); MS, *m/z* (%) = 312 (M^.+^+1, 100,), 285 (M^.+^- CN, 4), 283 (M^.+^-N~2~, 33), 257 (M^.+^-CN~3~, 3), 255 (M^.+^-CH~2~N~3~, 16) and 227 (M^.+^-CH~2~N~5~, 8); Anal. Calc. for C~19~H~13~N~5~ (311.34): C, 73.30; H, 4.21; N, 22.49%, found: C, 73.27; H, 4.22; N, 22.53%.

*8-Phenyl-5-p-tolylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**2b**). Yield 76%, 0.25 g, mp 247--248 °C; IR (υ~max~, cm^−1^): 1643 (pyrazole ring C=N), 1577 (triazole ring C=N), and 1454 (C=C); ^1^H NMR (DMSO-*d6*, δ~H~, ppm): 2.39 (s, 3H, CH3), 7.03 (d, 2H, aromatic-H), 7.26 (s, 1H, pyrazole-H),7.39--7.51 (m, 5H, aromatic-H), 7.44 (s, 1H, pyrimidine-H), 7.65 (d, 2H, aromatic-H) and 8.96 (s, 1H, triazole-H); MS, *m/z* (%) = 327 (M^.+^+2, 17), 325 (M^.+^, 100), 297 (M^.+^-N2, 24), 282 (M^.+^-CH~3~N~2~, 8),255 (M.+-C~2~H~4~N~3~, 7) and 227 (M^.+^-C~2~H~4~N~5~, 10); Anal. Calc. for C~20~H~15~N~5~ (325.37): C, 73.83; H, 4.65;N, 21.52%, found: C, 73.87; H, 4.62; N, 21.55%.

*5-(p-Methoxyphenyl)-8-phenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**2c**). Yield 74%, 0.25 g, mp 237--238 °C; IR (υ~max~, cm^−1^): 1643 (pyrazole ring C=N), 1587 (triazole ring C=N), and 1454 (C=C); ^1^H NMR (CDCl3, δ~H~, ppm): 3.92 (s, 3H, [CH~3~]{.ul}), 6.93 (s, 1H, pyrazole-H), 7.10 (d, 2H, aromatic- H), 7.40--7.48 (m, 3H, aromatic-H), 7.44 (s, 1H, pyrimidine-H), 7.57 (d, 2H, aromatic-H), 8.05 (d, 2H, aromatic-H) and 8.55 (s, 1H, triazole-H); MS, *m/z* (%) = 343 (M^.+^+2, 15), 341 (M^.+^, 100), 326 (M^.+^- CH~3~, 3), 313(M^.+^-N~2~, 10), 299 (M^.+^-CH~2~N~2~, 8), 285 (M^.+^-C~2~H~4~N~2~, 2) and 270 (M^.+^-C~2~H~3~N~2~O, 11); Anal. Calc. for C~20~H~15~N~5~O (341.37): C, 70.37; H, 4.43; N, 20.52%, found: C, 70.40; H, 4.40; N, 20.55%.

*5-(p-Chlorophenyl)-8-phenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**2d**). Yield 71%, 0.25 g, mp 299--300 °C; IR (υ~max~, cm^−1^): 1643 (pyrazole ring C=N), 1583 (triazole ring C=N), and 1467 (C=C); ^1^H NMR (DMSO-*d~6~*, δ~H~, ppm): 7.33 (s, 1H, pyrazole-H), 7.43 (s, 1H, pyrimidine-H), 7.44--7.52 (m, 3H, aromatic-H), 7.66 (d, 2H, aromatic-H), 7.79 (d, 2H, aromatic-H), 8.04 (d, 2H, aromatic-H) and 9.00 (s, 1H, triazole-H); MS, *m/z* (%) = 347 (M^.+^+1, 52), 345 (M^.+^-1, 100), 319 (M^.+^-HCN, 8), 317 (M^.+^-HN~2~, 17), 289 (M^.+^-C~2~H~5~N~2~, 6), 282 (M^.+^-HClN~2~, 13), 255 (M^.+^-C~2~H~4~ClN~2~, 16) and 227 (M^.+^- C~3~H~6~ClN~3~, 8); Anal. Calc. for C~19~H~12~ClN~5~ (345.79): C, 66.00; H, 3.50; N, 20.25%, found: C, 59.98; H, 3.50; N, 20.22%.

### 3.2.2. 5-Aryl-6-bromo-8-phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo\[4,3-*a*\]pyrimidines **3a-d**

A solution of bromine (0.06 mL, 1.2 mmol) in acetic acid (10 mL) was gradually added to a suspension of 5-aryl-8-phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo\[4,3-*a*\]pyrimidines **2a-d** (1 mmol) in acetic acid (10 mL) with stirring for 3 h at room temperature. The precipitated 5-aryl-6-bromo-8- phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo-\[4,3-*a*\]pyrimidines **3a-d** were filtered, washed with water, dried and crystallized from EtOH as colorless needles.

*6-Bromo-5,8-diphenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**3a**). Yield 75%, 0.30 g, mp 235--236 °C; IR (υ~max~, cm^−1^): 1640 (pyrazole ring C=N), 1580 (triazole ring C=N), and 1455 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 6.92 (s, 1H, pyrazole-H), 7.43--7.69 (m, 8H, aromatic-H), 8.14 (d, 2H, aromatic-H) and 8.58 (s, 1H, triazole-H); MS, *m/z* (%) = 390 (M^.+^, 100), 362 (M^.+^-N~2~, 13), 310 (M^.+^- Br, 2), 282 (M^.+^-BrN~2~, 13), 255 (M^.+^-CHBrN~3~, 12) and 227 (M^.+^-CHBrN~5~, 6); Anal. Calc. for C~19~H~12~BrN~5~ (390.24): C, 58.48; H, 3.10; N, 17.95%, found: C, 58.52; H, 3.08; N, 17.90%.

*6-Bromo-8-phenyl-5-p-tolylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**3b**). Yield 75%, 0.30 g, mp 215--216 °C; IR (υ~max~, cm^−1^): 1636 (pyrazole ring C=N), 1578 (triazole ring C=N), and 1421 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.49 (s, 3H, [CH~3~]{.ul}), 6.90 (s, 1H, pyrazole-H), 7.41--7.57 (m, 7H, aromatic-H), 8.14 (d, 2H, aromatic-H) and 8.60 (s, 1H, triazole-H); MS, *m/z* (%) = 407 (M^.+^+3, 8), 405 (M^.+^+1, 100), 377 (M^.+^-HCN, 8), 324 (M^.+^-Br, 2), 281 (M^.+^-CH~3~BrN~2~, 6) and 254 (M^.+^-C~2~H~4~BrN~3~, 5); Anal. Calc. for C~20~H~14~BrN~5~ (404.26): C, 59.42; H, 3.49; N, 17.32%, found: C, 59.39; H, 3.45; N, 17.27%.

*6-Bromo-5-(p-methoxyphenyl)-8-phenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**3c**). Yield 71%, 0.30 g, mp 213--214 °C; IR (υ~max~, cm^−1^): 1632 (pyrazole ring C=N), 1587 (triazole ring C=N), and 1427 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 3.90 (s, 3H, O[CH~3~]{.ul}), 6.81 (s, 1H, pyrazole-H),7.09 (d, 2H, aromatic-H), 7.44--7.56 (m, 3H, aromatic-H),7.59 (d, 2H, aromatic-H), 8.10 (d, 2H, aromatic-H) and 8.57 (s, 1H, triazole-H); MS, *m/z* (%) = 422 (M^.+^+2, 100), 420 (M^.+^, 80), 405 (M^.+^-CH~3~, 3), 391 (M^.+^- HN~2~, 8), 378 (M^.+^-CH~2~N~2~, 5), 350 (M^.+^- C~2~H~4~N~3~, 6), 340 (M^.+^-Br, 3), 313 (M^.+^-CHBrN, 4), 281 (M^.+^- CH~3~BrN~2~O, 5) and 269 (M^.+^-C~2~H~3~BrN~2~O, 13); Anal. Calc. for C~20~H~14~BrN~5~O (420.26): C, 57.16; H, 3.36; N, 16.66%, found: C, 57.20; H, 3.38; N, 16.70%.

*6-Bromo-5-(p-chlorophenyl)-8-phenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**3d**). Yield 71%, 0.30 g, mp 238--239 °C; IR (υ~max~, cm^−1^): 1637 (pyrazole ring C=N), 1580 (triazole ring C=N), and 1414 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 6.92 (s, 1H, pyrazole-H), 7.47--7.66 (m, 7H, aromatic-H), 8.14 (d, 2H, aromatic-H) and 8.55 (s, 1H, triazole-H); MS, *m/z* (%) = 429 (M^.+^+4, 3), 428 (M^.+^+3, 38), 426 (M^.+^+1, 100), 424 (M^.+^-1, 76), 398 (M^.+^-HCN, 11), 317 (M^.+^-BrN~2~, 8), 289 (M^.+^-CH~2~BrN~3~, 8), 281 (M^.+^- HBrClN~2~, 15), 253 (M^.+^-C~2~H~5~BrClN~2~, 10) and 226 (M^.+^-C~3~H~6~BrClN~3~, 7); Anal. Calc. for C~19~H~11~BrClN~5~ (424.68): C, 53.74; H, 2.61; N, 16.49%; found: C, 53.72; H, 2.57; N, 16.50%.

### 3.2.3. 5-Aryl-6-iodo-8-phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo\[4,3-*a*\]pyrimidines **4a-d**

A solution of iodine monochloride (0.2 g, 1.2 mmol) in acetic acid (10 mL) was gradually added to a suspension of 5- aryl-8-phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo\[3,4-*a*\]pyrimidines **2a-d** (1mmol) in acetic acid (10 mL) with stirring for 3 h at room temperature. The reaction mixture was then poured onto crushed ice and the precipitated 5-aryl-6-iodo-8-phenylpyrazolo\[1,5,*c*\]-1,2,4-triazolo\[3,4- *a*\]pyrimidines **4a-d** were filtered, washed with water, dried and crystallized from EtOH as colorless needles.

*6-Iodo-5,8-diphenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**4a**). Yield 91%, 0.40 g, mp 281--282 °C; IR (υ~max~, cm^-1^): 1640 (pyrazole ring C=N), 1575 (triazole ring C=N), and 1405 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 6.94 (s, 1H, pyrazole-H), 7.50-7.69 (m, 8H, aromatic-H), 8.10 (d, 2H, aromatic-H) and 8.61 (s, 1H, triazole-H); MS, *m/z* (%) = 437 (M^.+^, 100), 409 (M^.+^-N~2~, 5), 310 (M^.+^-I,7), 282 (M^.+^-IN~2~, 10), 242 (M^.+^-C~2~H~2~IN~3~, 4) and 227 (M^.+^-C~3~H~5~IN~3~, 8); Anal. Calc. for C~19~H~12~IN~5~ (437.24): C, 52.19; H, 2.77; N, 16.02%, found: C, 52.17; H, 2.80; N, 16.00%.

*6-Iodo-8-phenyl-5-p-tolylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**4b**). Yield 89%, 0.40 g, mp 245--246 °C; IR (υ~max~, cm^−1^): 1633 (pyrazole ring C=N), 1576 (triazole ring C=N), and 1416 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.49 (s, 3H, [CH~3~]{.ul}), 6.90 (s, 1H, pyrazole-H), 7.41-7.69 (m, 7H, aromatic-H), 8.08 (d, 2H, aromatic-H) and 8.60 (s, 1H, triazole-H); MS, *m/z* (%) = 453 (M^.+^+2, 9), 452 (M^.+^+1, 100), 423 (M^.+^-N~2~, 5), 325 (M^.+^+1-I, 12), 296 (M^.+^-IN~2~, 9) and 269 (M^.+^-CHIN~3~, 10); Anal. Calc. for C~20~H~14~IN~5~ (451.26): C, 53.23; H, 3.13; N, 15.52%, found: C, 53.27; H, 3.15; N, 15.50%.

*6-Iodo-5-(p-methoxyphenyl)-8-phenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**4c**). Yield 85%, 0.40 g, mp 225--226 °C; IR (υ~max~, cm^−1^): 1623 (pyrazole ring C=N), 1572 (triazole ring C=N), and 1458 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 3.93 (s, 3H, O[CH~3~]{.ul}), 6.86 (s, 1H, pyrazole-H), 7.12 (d, 2H, aromatic-H), 7.48--7.51 (m, 3H, aromatic-H), 7.61 (d, 2H, aromatic-H), 8.10 (d, 2H, aromatic-H) and 8.61 (s, 1H, triazole-H); MS, *m/z* (%) = 470 (M^.+^+3, 3), 468 (M^.+^+1, 100),439 (M^.+^-N~2~, 6), 341 (M^.+^+1-I, 12), 313 (M^.+^-CHIN, 4), 285 (M^.+^-CHIN~3~, 7), 269 (M^.+^-C~2~H~3~IN~2~O, 12) and 255 (M^.+^- C~2~H~3~IN~3~O, 4); Anal. Calc. for C~20~H~14~IN~5~O (467.26): C, 51.41; H, 3.02; N, 14.99%, found: C, 51.44; H, 3.00; N, 15.02%.

*5-(p-Chlorophenyl)-6-iodo-8-phenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**4d**). Yield 85%, 0.40 g, mp 270--271 °C; IR (υ~max~, cm^−1^): 1632 (pyrazole ring C=N), 1576 (triazole ring C=N), and 1410 (C=C); ^1^H NMR (DMSO-*d~6~*, δ~H~, ppm): 7.02 (s, 1H, pyrazole-H), 7.49--7.54 (m, 3H, aromatic-H), 7.65 (d, 2H, aromatic-H), 7.80 (d, 2H, aromatic-H), 7.92 (d, 2H, aromatic-H) and 9.04 (s, 1H, triazole-H); MS, *m/z* (%) = 475 (M^.+^+3, 3), 472 (M^.+^, 100), 443 (M^.+^-HN~2~, 3), 345 (M^.+^-I, 7), 309 (M^.+^-ClI, 2), 289 (M^.+^-CH~2~IN~3~, 5), 282 (M^.+^-CHClIN, 8) and 241 (M^.+^-C~2~H~2~ClIN~3~, 9); Anal. Calc. for C~19~H~11~ClIN~5~ (471.68): C, 48.38; H, 2.35; N, 14.85%, found: C, 48.40; H, 2.40; N, 14.90%.

### 3.2.4. 5-Aryl-6-nitro-8-phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo\[4,3-*a*\]pyrimidines **5a-d**

A mixture of nitric acid (d 1.41, 1 mL) and sulfuric acid (d 1.84, 1 mL) in glacial acetic acid (10 mL) was gradually added to a suspension of 5-aryl-8-phenylpyrazolo\[1,5-*c*\]-1,2,4-triazolo\[4,3- *a*\]pyrimidines **2a-d** (1 mmol) in glacial acetic acid (10 mL) with stirring for 3 h at room temperature. The reaction mixture was then poured onto cold water with stirring and the yellow precipitated solids were filtered, washed with cold water, dried and crystallized from EtOH to give the title compounds **5a-d** as yellow needles.

*6-Nitro-5,8-diphenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**5a**). Yield 83%, 0.30 g, mp 241--242 °C; IR (υ~max~, cm^−1^): 1649 (pyrazole ring C=N), 1579 (triazole ring C=N), and 1462 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 6.93 (s, 1H, pyrazole-H), 7.40--7.44 (m, 6H, aromatic-H), 7.62 (d, 2H, aromatic-H), 8.03 (d, 2H, aromatic-H) and 8.52 (s, 1H, triazole-H); MS, *m/z* (%) = 356 (M^.+^, 7), 326 (M^.+^-H~2~N~2~, 4), 311 (M^.+^+1-NO~2~, 100), 283 (M^.+^-CHN~2~O~2~, 27), 271 (M^.+^ +1-CN~3~O~2~, 2) and 255 (M^.+^-CHN~4~O~2~, 13); Anal. Calc. for C~19~H~12~N~6~O~2~ (356.34): C, 64.04; H, 3.39; N, 23.58%, found: C, 64.00; H, 3.40; N, 23.60%.

*6-Nitro-8-phenyl-5-p-tolylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**5b**). Yield 81%, 0.30 g, mp 243--244 °C; IR (υ~max~, cm^−1^): 1643 (pyrazole ring C=N), 1578 (triazole ring C=N), and 1415 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.47 (s, 3H, [CH~3~]{.ul}), 6.90 (s, 1H, pyrazole-H), 7.37--7.45 (m, 5H, aromatic-H), 7.51 (d, 2H, aromatic-H), 8.03 (d, 2H, aromatic-H) and 8.54 (s, 1H, triazole-H); MS, *m/z* (%) = 370 (M^.+^, 4), 340 (M^.+^-H~2~N~2~, 2), 325 (M^.+^+1-NO~2~, 100), 309 (M^.+^-CH~3~NO~2~, 1), 297 (M^.+^-CHN~2~O~2~, 22) and 269 (M^.+^-C~2~H~3~N~3~O~2~, 9); Anal. Calc. for C~20~H~14~N~6~O~2~ (370.36): C, 64.86; H, 3.81; N, 22.69%, found: C, 64.90; H, 3.80; N, 22.72%.

*5-(p-Methoxyphenyl)-6-nitro-8-phenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**5c**), Yield 77%, 0.30 g, mp 250--251 °C; IR (υ~max~, cm^−1^): 1637 (pyrazole ring C=N), 1585 (triazole ring C=N), and 1420 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 3.89 (s, 3H, O[CH~3~]{.ul}), 6.97 (s, 1H, pyrazole-H), 7.45--7.47 (m, 3H, aromatic-H), 7.62 (d, 2H, aromatic-H), 7.79 (d, 2H, aromatic-H), 8.02 (d, 2H, aromatic-H) and 8.75 (s, 1H, triazole-H); MS, *m/z* (%) = 388 (M^.+^+2, 15), 387 (M^.+^+1, 100), 356 (M^.+^-CH~2~O, 7), 339 (M^.+^-HNO~2~, 7), 312 (M^.+^-CH~2~N~2~O~2~, 4), 310 (M^.+^-CH~4~N~2~O~2~, 11), 284 (M^.+^-C~3~H~6~N~2~O~2~, 5) and 251 (M^.+^-C~7~H~7~N~2~O, 16); Anal. Calc. for C~20~H~14~N~6~O~3~ (386.36): C, 62.17; H, 3.65; N, 21.75%, found: C, 62.20; H, 3.61; N, 21.73%.

*5-(p-Chlorophenyl)-6-nitro-8-phenylpyrazolo\[1,5-c\]-1,2,4-triazolo\[4,3-a\]pyrimidine* (**5d**). Yield 77%, 0.30 g, mp 306--307 °C; IR (υ~max~, cm^−1^): 1641 (pyrazole ring C=N), 1583 (triazole ring C=N), and 1416 (C=C); ^1^H NMR (DMSO-*d~6~*, δ~H~, ppm): 7.33 (s, 1H, pyrazole-H), 7.43 (t, 1H, aromatic-H), 7.50 (t, 2H, aromatic-H), 7.66 (d, 2H, aromatic-H), 7.79 (d, 2H, aromatic-H), 8.03 (d, 2H, aromatic-H) and 8.99 (s, 1H, triazole-H); MS, *m/z* (%) = 391 (M^.+^, 3), 349 (M^.+^-CH~2~N~2~, 3), 347 (M^.+^-N~2~O, 46), 345 (M^.+^-NO~2~, 100), 317 (M^.+^-N~3~O~2~, 17), 289 (M^.+^-C~2~H~4~N~3~O~2~, 7), 282 (M^.+^-C~6~H~5~O~2~, 15), 254 (M^.+^-C~7~H~4~ClN, 22) and 227 (M^.+^-C~7~H~3~ClN~3~, 12); Anal. Calc. for C~19~H~11~ClN~6~O~2~ (390.78): C, 58.40; H, 2.84; N, 21.51%, found: C, 58.44; H, 2.80; N, 21.53%.

### 3.2.5. 5-Aryl-7-formylhydrazino-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **6a-d**

A suspension of 5-aryl-7-hydrazino-2-phenylpyrazolo\[1,5-*c*\]pyrimidines (**1a-d**, 1mmol) and ethyl formate (5 mL) was heated under reflux for 3 h. The product which separated upon cooling was filtered, washed with EtOH and crystallized from EtOH to give the title compounds **6a-d** as colorless needles.

*7-Formylhydrazino-2,5-Diphenylpyrazolo\[1,5-c\]pyrimidine* (**6a**). Yield 76%, 0.25 g, mp 177--178 °C; IR (~υmax~, cm^−1^): 3368 (NH), 1700 (C=O), 1624 (pyrazole ring C=N), 1568 (pyrimidine ring C=N), and 1455 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 4.80 (s, 2H, exchangeable 2NH), 6.72 (s, 1H, pyrazole-H), 7.29 (s, 1H, pyrimidine-H), 7.30-7.49 (m, 8H, aromatic-H), 7.98 (d, 2H, aromatic-H) and 8.08 (s, 1H, [CHO]{.ul}); MS, *m/z* (%) = 330 (M^.+^+1, 2), 302 (M^.+^+1-CO, 100), 286 (M^.+^-CHNO, 23), 272 (M^.+^-CHN~2~O, 81), 257 (M^.+^-C~2~H~4~N~2~O, 2), 244 (M^.+^-C~2~H~3~N~3~O, 17) and 228 (M^.+^-C~2~H~5~N~4~O, 6); Anal. Calc. for C~19~H~15~N~5~O (329.36): C, 69.29; H, 4.59; N, 21.26%, found: C, 69.30; H, 4.62; N, 21.30%.

*7-Formylhydrazino-2-phenyl-5-p-tolylpyrazolo\[1,5-c\]pyrimidine* (**6b**). Yield 71%, 0.25 g, mp 132--133 °C; IR (υ~max~, cm^−1^): 3315 (NH), 1701 (C=O), 1610 (pyrazole ring C=N), 1572 (pyrimidine ring C=N), and 1447 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.42 (s, 3H, [CH~3~]{.ul}), 4.77 (s, 2H, exchangeable 2NH), 6.70 (s, 1H, pyrazole-H), 7.28 (s, 1H, pyrimidine-H), 7.29-7.49 (m, 7H, aromatic-H), 7.96 (d, 2H, aromatic- H) and 7.98 (s, 1H, [CHO]{.ul}); MS, *m/z* (%) = 344 (M^.+^+1, 2), 316 (M^.+^+1-CO, 100), 300 (M^.+^-CHNO, 33), 286 (M^.+^-CHN~2~O, 85), 270 (M^.+^-C~2~H~5~N~2~O, 4), 259 (M^.+^-C~2~H~2~N~3~O, 7) and 227 (M^.+^-C~8~H~6~N, 10); Anal. Calc. for C~20~H~17~N~5~O (343.38): C, 69.96; H, 4.99; N, 20.40%, found: C, 70.02; H, 5.02; N, 20.44%

*7-Formylhydrazino-5-(p-methoxyphenyl)-2-phenylpyrazolo\[1,5-c\]pyrimidine* (**6c**). Yield 69%, 0.25 g, mp 157--158 °C; IR (υ~max~, cm^−1^): 3265(NH), 1708 (C=O), 1667 (pyrazole ring C=N), 1585 (pyrimidine ring C=N), and 1448 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 3.87 (s, 3H, O[CH~3~]{.ul}), 4.73 (s, 2H, exchangeable 2NH), 6.68 (s, 1H, pyrazole-H), 7.19 (s, 1H, pyrimidine-H), 7.20--7.46 (m, 3H, aromatic- H), 7.95--7.97 (m, 4H, aromatic-H), 7.98 (d, 2H, aromatic-H) and 8.00 (s, 1H, [CHO]{.ul}); MS, *m/z* (%) = 361 (M^.+^+2, 5), 359 (M^.+^, 30), 332 (M^.+^+1-CO, 100), 316 (M^.+^-CHNO, 23), 302 (M^.+^-CHN~2~O, 78), 287 (M^.+^-C~2~H~4~N~2~O, 12) and 275 (8, M^.+^-C~2~H~2~N~3~O); Anal. Calc. for C~20~H~17~N~5~O~2~ (359.38): C, 66.84; H, 4.77; N, 19.49%, found: C, 66.80; H, 4.82; N, 19.50%.

*5-(p-Chlorophenyl)-7-formylhydrazino-2-phenylpyrazolo\[1,5-c\]pyrimidine* (**6d**). Yield 69%, 0.25 g, mp 175--176 °C; IR (υ~max~, cm^−1^): 3315 (NH), 1700 (C=O), 1615 (pyrazole ring C=N), 1575 (pyrimidine ring C=N), and 1450 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 4.76 (s, 2H, exchangeable 2NH), 6.72 (s, 1H, pyrazole-H), 7.28 (s, 1H, pyrimidine-H), 7.41--7.46 (m, 5H, aromatic-H), 7.95--7.99 (m, 4H, aromatic- H) and 8.00 (s, 1H, [CHO]{.ul}); MS, *m/z* (%) = 361 (M^.+^-3, 2,), 335 (M^.+^+1-CO, 19), 320 (M^.+^-CHNO, 100), 305 (M^.+^-CH~2~N~2~O, 47), 294 (M^.+^-C~2~HN~2~O, 10), 269 (M^.+^-C~6~H~6~O, 5) and 242 (M^.+^-C~7~H~7~NO, 5); Anal. Calc. for C~19~H~14~ClN~5~O (363.80): C, 62.73; H, 3.88; N, 19.25%, found: C, 62.70; H, 3.90; N, 19.30%.

### 3.2.6. 7-Acetylhydrazino-5-aryl-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **7a-d**

5-Aryl-7-hydrazino-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **1a-d** (1mmol) and glacial acetic acid (10 mL) was heated at reflux for 3 h. The reaction mixture was poured onto crushed ice and the product which separated was filtered, washed with water, dried and crystallized from EtOH to give the title compounds **7a-d** as colorless needles.

*7-Acetylhydrazino-2,5-diphenylpyrazolo\[1,5-c\]pyrimidine* (**7a**). Yield 88%, 0.30 g, mp 217--218 °C; IR (υ~max~, cm^−1^): 3150 (NH), 1661 (C=O), 1628 (pyrazole ring C=N), 1568 (pyrimidine ring C=N), and 1459 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.21(s, 3H, CO[CH~3~]{.ul}), 6.67 (s, 1H, pyrazole-H), 7.21 (s, 1H, pyrimidine-H), 7.30--7.51 (m, 5H, aromatic-H), 7.84--7.96 (m, 5H, aromatic-H), 8.01 (s, 1H, exchangeable NH) and 8.48 (s, 1H, exchangeable NHCO); MS, *m/z* (%) = 343 (M^.+^, 100), 328 (M^.+^-CH~3~, 1), 301 (M^.+^-COCH~2~, 59), 286 (M^.+^-NCOCH~3~, 18) and 243 (M^.+^-C~3~H~6~N~3~O, 11); Anal. Calc. for C~20~H~17~N~5~O (343.38): C, 69.96; H, 4.99; N, 20.40%, found: C, 70.00; H, 5.02; N, 20.43%.

*7-Acetylhydrazino-2-phenyl-5-p-tolylpyrazolo\[1,5-c\]pyrimidine* (**7b**). Yield 83%, 0.30 g, mp 224--225 °C; IR (υ~max~, cm^−1^): 3252 (NH), 1659 (C=O), 1618 (pyrazole ring C=N), 1556 (pyrimidine ring C=N), and 1445 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.23(s, 3H, [CH~3~]{.ul}), 2.36 (s, 3H, CO[CH~3~]{.ul}), 6.70 (s, 1H, pyrazole-H), 7.19 (d, 2H, aromatic-H), 7.26 (s, 1H, pyrimidine-H), 7.36--7.48 (m, 3H, aromatic-H), 7.79 (d, 2H, aromatic-H), 7.97 (d, 2H, aromatic-H), 8.14 (s, 1H, exchangeable NH) and 8.31 (s, 1H, exchangeable NHCO); MS, *m/z* (%) = 358 (M^.+^+1, 100), 315 (M^.+^-COCH~2~, 63), 300 (M^.+^-NCOCH~3~, 19), 288 (M^.+^-C~3~H~3~NO, 6) and 259 (M^.+^-C~3~H~4~N~3~O, 5); Anal. Calc. for C~21~H~19~N~5~O (357.41): C, 70.57; H, 5.36; N, 19.59%, found: C, 70.60; H, 5.32; N, 19.55%.

*7-Acetylhydrazino-5-p-methoxyphenyl-2-phenylpyrazolo\[1,5-c\]pyrimidine* (**7c**). Yield 81%, 0.30 g, mp 193--194 °C; IR (υ~max~, cm^−1^): 3283 (NH), 1664 (C=O), 1618 (pyrazole ring C=N), 1564 (pyrimidine ring C=N), and 1448 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.24 (s, 3H, CO[CH~3~]{.ul}), 3.78 (s, 3H, O[CH~3~]{.ul}), 6.63 (s, 1H, pyrazole-H), 6.88 (d, 2H, aromatic-H), 7.07 (s, 1H, pyrimidine-H), 7.36--7.50 (m, 3H, aromatic-H), 7.76 (d, 2H, aromatic-H), 7.91 (d, 2H, aromatic-H), 8.13 (s, 1H, exchangeable NH) and 8.91 (s, 1H, exchangeable NHCO); MS, *m/z* (%) = 374 (M^.+^+1, 100), 331 (M^.+^-COCH~2~, 38), 316 (M^.+^-NCOCH~3~, 16), 302 (M^.+^-NNCOCH~3~, 56), 287 (M^.+^-C~3~H~6~N~2~O, 8) and 259 (M^.+^- C~4~H~8~N~3~O, 19); Anal. Calc. for C~21~H~19~N~5~O~2~ (373.41): C, 67.55; H, 5.13; N, 18.76%, found: C, 67.58; H, 5.16; N, 18.80%.

*7-Acetylhydrazino-5-p-Chlorophenyl-2-phenylpyrazolo\[1,5-c\]pyrimidine* (**7d**). Yield 79%, 0.30 g, mp 246--247 °C; IR (υ~max~, cm^−1^): 3306 (NH), 1664 (C=O), 1613 (pyrazole ring C=N), 1572 (pyrimidine ring C=N), and 1447 (C=C); ^1^H NMR (DMSO-*d~6~*, δ~H~, ppm): 2.04 (s, 3H, CO[CH~3~]{.ul}), 7.08 (s, 1H, pyrazole-H), 7.67 (s, 1H, pyrimidine-H), 7.41--7.52 (m, 5H, aromatic-H), 8.09 (d, 2H, aromatic-H), 9.81 (s, 1H, exchangeable NH) and 10.14 (s, 1H, exchangeable NHCO); MS, *m/z* (%) = 382 (M^.+^+4, 1), 381 (M^.+^+3, 4), 379 (M^.+^+1, 44), 378 (M^.+^, 100), 336 (M^.+^-COCH~2~, 65), 320 (M^.+^-NHCOCH~3~, 16), 306 (M^.+^-NNHCOCH~3~, 77) and 270 (M^.+^-C~2~H~5~ClN~2~O, 10); Anal. Calc. for C~20~H~16~ClN~5~O (377.83): C, 63.58; H, 4.27; N, 18.54%, found: C, 63.61; H, 4.26; N, 18.60%.

### 3.2.7. 7-Acetylhydrazino-5-aryl-3,4-dibromo-2\--phenylpyrazolo\[1,5-*c*\]pyrimidines **8a-d**

A solution of bromine (0.12 mL, 2.4 mmol) in acetic acid (10 mL) was gradually added to a suspension of 7-acetylhydrazino-5-aryl-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **7a-d** (1 mmol) in acetic acid (10 mL) with stirring for 3 h at room temperature. The precipitated 7-acetylhydrazino-5-aryl-3,4- dibromo-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **8a-d** were filtered, washed with water, dried and crystallized from EtOH as colorless needles.

*7-Acetylhydrazino-3,4-dibromo-2,5-diphenylpyrazolo\[1,5-c\]pyrimidine* (**8a**). Yield 80%, 0.40 g, mp 229--230 °C; IR (υ~max~, cm^−1^): 3451 (NH), 1657 (C=O), 1644 (pyrazole ring C=N), 1560 (pyrimidine ring C=N), and 1439 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.09 (s, 3H, CO[CH~3~]{.ul}), 7.44--7.53 (m, 6H, aromatic-H), 7.63 (d, 2H, aromatic-H), 7.94 (d, 2H, aromatic-H) and 8.01 (s, 2H, exchangeable NH and exchangeable NHCO); MS, *m/z* (%) = 505(M^.+^+4, 4), 503 (M^.+^+2, 38), 501 (M^.+^, 100), 459 (M^.+^- COCH~2~, 80), 444 (M^.+^-NCOCH~3~, 14), 429 (M^.+^-NNHCOCH~3~, 40), 423 (M^.+^+2-Br, 21), 421 (M^.+^-Br, 19) and 341 (M^.+^-Br2, 2); Anal. Calc. for C~20~H~15~Br~2~N~5~O (501.17): C, 47.93; H, 3.02; N, 13.97%, found: C, 47.95; H, 3.06; N, 14.00%.

*7-Acetylhydrazino-3,4-dibromo-2-phenyl-5-p-tolylpyrazolo\[1,5-c\]pyrimidine* (**8b**). Yield 77%, 0.40 g, mp 212--213 °C; IR (υ~max~, cm^−1^): 3280 (NH), 1664 (C=O), 1618 (pyrazole ring C=N), 1562 (pyrimidine ring C=N), and 1439 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.10 (s, 3H, [CH~3~]{.ul}), 2.40 (s, 3H, CO[CH~3~]{.ul}), 7.46--7.55 (m, 5H, aromatic-H), 7.86 (d, 2H, aromatic-H), 7.93 (d, 2H, aromatic-H), 8.04 (s, 1H, exchangeable NH) and 8.06 (s, 1H, exchangeable NHCO); MS, *m/z* (%) = 519 (M^.+^+4, 1), 517 (M^.+^+2, 15), 515 (M^.+^, 33), 473 (M^.+^-COCH~2~, 18), 458 (M^.+^-NCOCH~3~, 2), 444 (M^.+^-NNCOCH~3~, 7), 442 (M^.+^-NHNHCOCH~3~, 5), 437 (M^.+^+2-Br, 100), 435 (M^.+^-Br, 84) and 355 (M^.+^-Br~2~, 1); Anal. Calc. for C~21~H~17~Br~2~N~5~O (515.20): C, 48.96; H, 3.33; N, 13.59%, found: C, 49.00; H, 3.36; N, 13.60%.

*7-Acetylhydrazino-3,4-dibromo-5-(p-methoxyphenyl)-2-phenylpyrazolo\[1,5-c\]-pyrimidine* (**8c**). Yield 75%, 0.40 g, mp 182--183 °C; IR (υ~max~, cm^−1^): 3269 (NH), 1668 (C=O), 1612 (pyrazole ring C=N), 1535 (pyrimidine ring C=N), and 1443 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.47 (s, 3H, CO[CH~3~]{.ul}), 3.79 (s, 3H, O[CH~3~]{.ul}), 7.48--7.62 (m, 3H, aromatic-H), 7.91 (d, 2H, aromatic-H), 8.04 (d, 2H, aromatic-H), 8.08 (d, 2H, aromatic-H), 10.05 (s, 1H, exchangeable NH) and 10.10 (s, 1H, exchangeable NHCO); MS, *m/z* (%) = 535(M^.+^+4, 1), 533 (M^.+^+2, 6), 531 (M^.+^, 10), 489 (M^.+^-COCH~2~, 6), 475 (M^.+^-NCOCH~2~, 13), 459 (M^.+^-NNHCOCH~3~, 23), 453 (M^.+^+2-Br, 73), 451 (M^.+^-Br, 61) and 370 (M^.+^+1-Br~2~, 1); Anal. Calc. for C~21~H~17~Br~2~N~5~O~2~ (531.20): C, 47.48; H, 3.23; N, 13.18%, found: C, 47.50; H, 3.26; N, 13.20%.

*7-Acetylhydrazino-5-(p-chlorophenyl)-3,4-dibromo-2-phenylpyrazolo\[1,5-c\]-pyrimidine* (**8d**). Yield 74%, 0.40 g, mp 226--227 °C; IR (υ~max~, cm^−1^): 3267 (NH), 1664 (C=O), 1620 (pyrazole ring C=N), 1570 (pyrimidine ring C=N), and 1437 (C=C); ^1^H NMR (DMSO-*d~6~*, δ~H~, ppm): 2.47 (s, 3H, CO[CH~3~]{.ul}), 7.49--7.57 (m, 5H, aromatic-H), 8.04 (d, 2H, aromatic-H), 8.15 (d, 2H, aromatic-H), 10.06 (s, 1H, exchangeable NH) and 10.17 (s, 1H, exchangeable NHCO); MS, *m/z* (%) = 538 (M^.+^+2, 2), 535 (M^.+^-1, 4), 493 (M^.+^- COCH~3~, 4), 463 (M^.+^-NHNHCOCH~3~, 3), 458 (M^.+^+2-Br, 20), 456 (M^.+^-Br, 100) and 376 (M^.+^-Br~2~, 1); Anal. Calc. for C~20~H~14~Br~2~ClN~5~O (535.62): C, 44.85; H, 2.63; N, 13.08%, found: C, 44.81; H, 2.60; N, 13.11%.

### 3.2.8. 7-Acetylhydrazino-5-aryl-3-iodo-2\--phenylpyrazolo\[1,5-*c*\]pyrimidines **9a-d**

A solution of iodine monochloride (0.2 g, 1.2 mmol) in acetic acid (10 mL) was gradually added to a suspension of 7-acetylhydrazino-5-aryl-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **7a-d** (1 mmol) in acetic acid (10 mL) with stirring for 3 h at room temperature. The reaction mixture was then poured onto crushed ice and the precipitated 7-acetylhydrazino-5-aryl-3-iodo-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **9a-d** were filtered, washed with water, dried and crystallized from EtOH as colorless needles.

*7-Acetylhydrazino-3-iodo-2,5-diphenylpyrazolo\[1,5-c\]pyrimidine* (**9a**). Yield 85%, 0.40 g, mp 229--230 °C; IR (υ~max~, cm^−1^): 3433 (NH), 1680 (C=O), 1618 (pyrazole ring C=N), 1549 (pyrimidine ring C=N), and 1438 (C=C); ^1^H NMR (DMSO-*d~6~*, δ~H~, ppm): 2.05 (s, 3H, CO[CH~3~]{.ul}), 7.29--7.80 (m, 10H, aromatic-H), 7.48 (s, 1H, pyrimidine-H), and 8.06 (s, 2H, exchangeable NHCO and exchangeable NH); MS, *m/z* (%) = 469 (M^.+^, 2), 451 (M^.+^- H~2~O, 4), 437 (M^.+^- CH~4~O, 2), 343 (M^.+^+1-I, 5), 300 (M^.+^- I-CH~2~CO, 32) and 385 (M^.+^ - CH~3~INO, 100); Anal. Calc. for C~20~H~16~IN~5~O (469.28): C, 51.19; H, 3.44; N, 14.92%, found: C, 51.20; H, 3.40; N, 14.88%.

*7-Acetylhydrazino-3-iodo-2-phenyl-5-p-tolylpyrazolo\[1,5-c\]pyrimidine* (**9b**). Yield 83%, 0.40 g, mp 204--205 °C; IR (υ~max~, cm^−1^): 3273 (NH), 1661 (C=O), 1610 (pyrazole ring C=N), 1564 (pyrimidine ring C=N), and 1433 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.26 (s, 3H, CH~3~), 2.42 (s, 3H, CO[CH~3~]{.ul}), 7.18 (s, 1H, pyrimidine-H), 7.28--7.30 (m, 3H, aromatic-H), 7.49--7.52 (m, 4H, aromatic-H), 7.84 (d, 2H, aromatic-H), 7.97 (s, 1H, exchangeable NH), and 7.99 (s, 1H, exchangeable NHCO); MS, *m/z* (%) = 484 (M^.+^+1, 83), 441 (M^.+^-COCH~2~, 34), 426 (M^.+^-NCOCH~3~, 12), 412 (M^.+^-NNCOCH~3~, 12), 410 (M^.+^ -NHNHCOCH~3~, 1) and 357 (M^.+^+1- I, 16); Anal. Calc. for C~21~H~18~IN~5~O (483.30): C, 52.19; H, 3.75; N, 14.49%, found: C, 52.50; H, 3.79; N, 14.52%.

*7-Acetylhydrazino-3-iodo-5-(p-methoxyphenyl)-2-phenylpyrazolo\[1,5-c\]-pyrimidine* (**9c**). Yield 80%, 0.40 g, mp 124--125 °C; IR (υ~max~, cm^−1^): 3290 (NH), 1711 (C=O), 1610 (pyrazole ring C=N), 1560 (pyrimidine ring C=N), and 1448 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.16 (s, 3H, CO[CH~3~]{.ul}), 3.87 (s, 3H, O[CH~3~]{.ul}), 6.99--7.49 (m, 7H, aromatic-H), 7.69 (s, 1H, pyrimidine-H), 8.01 (d, 2H, aromatic-H) and 9.28 (s, 2H, exchangeable NH and exchangeable NHCO); MS, *m/z* (%) = 484 (M^.+^-CH~3~, 1), 343 (M^.+^- NCOCH~2~, 3), 373 (M^.+^+1-I, 6) and 372 (M^.+^- I, 1); Anal. Calc. for C~21~H~18~IN~5~O~2~ (499.30): C, 50.52; H, 3.63; N, 14.03%. Found: C, 50.55; H, 3.59; N, 14.06%.

*7-Acetylhydrazino-5-(p-chlorophenyl)-3-iodo-2-phenylpyrazolo\[1,5-c\]pyrimidine* (**9d**). Yield 80%, 0.40 g, mp 207--208 °C; IR (υ~max~, cm^−1^): 3273 (NH), 1662 (C=O), 1616 (pyrazole ring C=N), 1566 (pyrimidine ring C=N), and 1439 (C=C); ^1^H NMR (DMSO-*d~6~*, δ~H~, ppm): 2.01 (s, 3H, CO[CH~3~]{.ul}), 7.14 (d, 2H, aromatic-H), 7.40 (s, 1H, pyrimidine-H), 7.49--7.54 (m, 3H, aromatic-H), 7.68 (d, 1H, aromatic-H), 7.80 (d, 1H, aromatic-H), 7.98 (d, 2H, aromatic-H),. 10.00 (s, 1H, exchangeable NH), and 10.16 (s, 1H, exchangeable NHCO); MS, *m/z* (%) = 506 (M^.+^+2, 45), 504 (M^.+^, 100), 463 (M^.+^+2-COCH~3~, 22), 461 (M^.+^-COCH~3~, 57), 446 (M^.+^-NHCOCH~3~, 15), 432 (M^.+^ -NNHCOCH~3~, 17), 379 (M^.+^+2-I, 10) and 377 (M^.+^-I, 24); Anal. Calc. for C~20~H~15~ClIN~5~O (503.72): C, 47.69; H, 3.00; N, 13.90%, found: C, 47.72; H, 2.99; N, 13.92%.

### 3.2.9. 7-Acetylhydrazino-5-aryl-3-nitro-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **10a-d**

A mixture of nitric acid (d 1.41, 1 mL) and sulfuric acid (d 1.84, 1 mL) in glacial acetic acid (10 mL) was gradually added to a suspension of 7-acetylhydrazino-5-aryl-2-phenylpyrazolo\[1,5- *c*\]pyrimidines **7a-d** (1 mmol) in glacial acetic acid (10 mL) with stirring for 3 h at room temperature. The reaction mixture was then poured onto cold water with stirring and the yellow precipitated solid were filtered, washed with cold water, dried and crystallized from EtOH to give the title compounds **10a-d** as yellow needles.

*7-Acetylhydrazino-3-nitro-2,5-diphenylpyrazolo\[1,5-c\]pyrimidine* (**10a**). Yield 77%, 0.30 g, mp 191--192 °C; IR (υ~max~, cm^−1^): 3436 (NH), 1743 (C=O), 1633 (pyrazole ring C=N), 1551 (pyrimidine ring C=N), and 1462 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 1.90 (s, 3H, CO[CH~3~]{.ul}), 7.37 (s, 1H, pyrimidine-H), 7.44--7.68 (m, 6H, aromatic-H), 7.97 (d, 2H, aromatic-H), 8.03 (d, 2H, aromatic-H), 8.46 (s, 1H, exchangeable NH), and 9.26 (s, 1H, exchangeable NHCO); MS, *m/z* (%) = 389 (M^.+^+1, 4), 360 (M^.+^- CO, 7), 346 (M^.+^-COCH~2~, 2), 332 (M^.+^-NCOCH~2~, 100), 316 (M^.+^-NNHCOCH~3~, 4), 302 (M^.+^-C~3~H~6~N~2~O, 17), 286 (M^.+^-C~2~H~2~N~2~O~3~, 10) and 258 (M^.+^-C~3~H~4~N~3~O~3~, 25); Anal. Calc. for C~20~H~16~N~6~O~3~ (388.38): C, 61.85; H, 4.15; N, 21.64%, found: C, 61.89; H, 4.12; N, 21.60%.

*7-Acetylhydrazino-3-nitro-2-phenyl-5-p-tolylpyrazolo\[1,5-c\]pyrimidine* (**10b**). Yield 75%, 0.30 g, mp 194--195 °C; IR (υ~max~, cm^−1^): 3371 (NH), 1745 (C=O), 1601 (pyrazole ring C=N), 1533 (pyrimidine ring C=N), and 1443 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 1.96 (s, 3H, [CH~3~]{.ul}), 2.44 (s, 3H, CO[CH~3~]{.ul}), 7.30--7.71 (m, 10H, aromatic-H and pyrimidine-H) and 8.44 (s, 2H, exchangeable NH and exchangeable NHCO); MS, *m/z* (%) = 403 (M^.+^+1, 2), 402 (M^.+^, 3), 401 (M^.+^-1, 16), 374 (M^.+^-CO, 8) and 346 (M^.+^-C~2~H~2~NO, 6); Anal. Calc. for C~21~H~18~N~6~O~3~ (402.41): C, 62.68; H, 4.51; N, 20.88%, found: C, 62.71; H, 4.50; N, 20.91%.

*7-Acetylhydrazino-5-(p-methoxyphenyl)-3-nitro-2-phenylpyrazolo\[1,5-c\]-pyrimidine* (**10c**). Yield 71%, 0.30 g, mp 132--133 °C; IR (υ~max~, cm^−1^): 3464 (NH), 1747 (C=O), 1696 (pyrazole ring C=N), 1531 (pyrimidine ring C=N), and 1454 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 1.81 (s, 3H, CO[CH~3~]{.ul}), 3.89 (s, 3H O[CH~3~]{.ul}), 7.00--7.71 (m, 10H, aromatic-H and pyrimidine-H) and 8.43 (s, 2H, exchangeable NH and exchangeable NHCO); MS, *m/z* (%) = 420 (M^.+^+2, 1), 358 (M^.+^-C~2~H~6~NO, 1), 334 (M^.+^ -C~3~H~4~N~2~O, 1) and 300 (M^.+^-C~2~H~4~N~3~O~3~, 3); Anal. Calc. for C~21~H~18~N~6~O~4~ (418.41): C, 60.28; H, 4.34; N, 20.09%, found: C, 60.31; H, 4.32; N, 20.13%.

*7-Acetylhydrazino-5-(p-chlorophenyl)-3-nitro-2-phenylpyrazolo\[1,5-c\]-pyrimidine* (**10d**). Yield 71%, 0.30 g, mp 174--175 °C; IR (υ~max~, cm^−1^): 3371 (NH), 1749 (C=O), 1597 (pyrazole ring C=N), 1533 (pyrimidine ring C=N), and 1443 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.13 (s, 3H, CO[CH~3~]{.ul}), 7.34--7.73 (m, 10H, aromatic-H and pyrimidine-H) and 8.45 (s, 2H, exchangeable NH and exchangeable NHCO); MS, *m/z* (%) = 423 (M^.+^, 1), 381 (M^.+^-COCH~2~, 1), 366 (M^.+^- NCOCH~3~, 1), 324 (M^.+^-C~3~H~5~N~3~O, 1) and 300 (M^.+^-C~6~H~5~NO~2~, 2); Anal. Calc. for C~20~H~15~ClN~6~O~3~ (422.82): C, 56.81; H, 3.58; N, 19.88%, found: C, 56.77; H, 3.61; N, 19.85%.

### 3.2.10. 7-Triacetylhydrazino-5-aryl-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **11a-d**

A suspension of 5-aryl-7-hydrazino-2-phenylpyrazolo\[1,5-*c*\]pyrimidines **1a-d** (1 mmol) in acetic anhydride (5 mL) was heated under reflux for 1 h and the mixture was cooled and poured onto crushed ice. The product that separated out was filtered off, washed with water and then dried. It was crystallized from EtOH to give the title compounds **11a-d** as colorlees needles.

*7-Triacetylhydrazino-2,5-diphenylpyrazolo\[1,5-c\]pyrimidine* (**11a**). Yield 83%, 0.35 g, mp 179--180 °C; IR (υ~max~, cm^−1^): 1736 (C=O), 1623 (pyrazole ring C=N), 1542 (pyrimidine ring C=N) and 1458 (C=C); ^1^H NMR (DMSO-*d~6~*, δ~H~, ppm): 2.45 (s,3H, CO[CH~3~]{.ul}), 2.48 (s, 3H, CO[CH~3~]{.ul}), 2.50 (s, 3H, CO[CH~3~]{.ul}), 7.28 (s, 1H, pyrazole-H), 7.44 (t, 2H, aromatic-H), 7.50 (t, 4H, aromatic-H), 7.99 (d, 2H, aromatic-H) , 8.05 (d, 2H, aromatic-H) and 8.24 (s, 1H, pyrimidine-H); MS, *m/z* (%) = 428 (M^.+^+1, 15), 385 (M^.+^-CH~2~CO, 15), 343 (M^.+^-2 CH~2~CO, 100), 301 (M^.+^-3 CH~2~CO, 65), 286 (M^.+^- C~6~H~6~NO~2~, 24), 272 (M^.+^-C~6~H~6~N~2~O~2~, 88) and 270 (M^.+^-C~6~H~8~N~2~O~2~, 26); Anal. Calc. for C~24~H~21~N~5~O~3~ (427.46): C, 67.44; H, 4.95; N, 16.38%, found: C, 67.40; H, 5.00; N, 16.40%.

*7-Triacetylhydrazino-2-phenyl-5-p-tolylpyrazolo\[1,5-c\]pyrimidine* (**11b**). Yield 80%, 0.35 g, mp 194--195 °C; IR (υ~max~, cm^−1^): 1726 (C=O), 1622 (pyrazole ring C=N), 1520 (pyrimidine ring C=N) and 1450 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.17(s, 3H, [CH~3~]{.ul}), 2.42 (s,3H, COCH~3~), 2.54 (s, 3H, CO[CH~3~]{.ul}), 2.56 (s, 3H, CO[CH~3~]{.ul}),6.90 (s, 1H, pyrazole-H), 7.28 (d, 2H, aromatic-H), 7.42--7.50 (m, 3H, aromatic-H), 7.72 (s, 1H, pyrimidine-H), 7.87 (d, 2H, aromatic-H) and 7.95 (d, 2H, aromatic-H); MS, *m/z* (%) = 443 (M^.+^+2, 2), 441 (M^.+^, 10), 399 (M^.+^-COCH~2~, 11), 357 (M^.+^-2COCH~2~, 100), 315 (M^.+^-3COCH~2~, 44) and 300 (M^.+^-C~6~H~7~NO~3~, 21); Anal. Calc. for C~25~H~23~N~5~O~3~ (441.48): C, 68.01; H, 5.25; N, 15.86%, found: C, 68.12; H, 5.22; N, 15.81%.

*7-Triacetylhydrazino-5-p-methoxyphenyl-2-phenylpyrazolo\[1,5-c\]pyrimidine* (**11c**). Yield 76%, 0.35 g, mp 132--133 °C; IR (υ~max~, cm^−1^): 1720 (C=O), 1614 (pyrazole ring C=N), 1510 (pyrimidine ring C=N), and 1448 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.53(s, 9H, 3CO[CH~3~]{.ul}), 3.86 (s, 3H, O[CH~3~]{.ul}), 6.87 (s, 1H, pyrazole-H), 6.98 (d, 2H, aromatic-H), 7.41--7.49 (m, 3H, aromatic-H), 7.65 (s, 1H, pyrimidine- H) and 7.91--7.95 (m, 4H, aromatic-H); MS, *m/z* (%) = 459 (M^.+^+2, 2), 457 (M^.+^, 17), 415 (M^.+^- COCH~2~, 19), 373 (M^.+^-2COCH~2~, 100), 331 (M^.+^-3COCH~2~, 39), 316 (M^.+^-C~6~H~7~NO~3~, 17) and 302 (M^.+^-C~7~H~9~NO~3~, 41); Anal. Calc. for C~25~H~23~N~5~O~4~ (457.48): C, 65.63; H, 5.07; N, 15.31%, found: C, 65.51; H, 5.05; N, 15.28%.

*7-Triacetylhydrazino-5-p-chlorophenyl-2-phenylpyrazolo\[1,5-c\]pyrimidine* (**11d**). Yield 76%, 0.35 g, mp 174--175 °C; IR (υ~max~, cm^−1^): 1722 (C=O), 1616 (pyrazole ring C=N), 1533 (pyrimidine ring C=N), and 1443 (C=C); ^1^H NMR (CDCl~3~, δ~H~, ppm): 2.52(s, 3H, CO[CH~3~]{.ul}), 2.56 (s, 6H, 2CO[CH~3~]{.ul}), 6.91 (s, 1H, pyrazole-H), 7.41--7.49 (m, 5H, aromatic-H), 7.70 (s, 1H, pyrimidine-H), 7.88 (d, 2H, aromatic-H) and 7.93 (d, 2H, aromatic-H); MS, *m/z* (%) = 464 (M^.+^+2, 1), 462 (M^.+^, 5), 420 (M^.+^-COCH~2~, 8), 378 (M^.+^-2COCH~2~, 58), 336 (M^.+^-3COCH~2~, 30), 320 (M^.+^-C~6~H~8~NO~3~, 13) and 306 (M^.+^-C~6~H~8~N~2~O~3~, 24); Anal. Calc. for C~24~H~20~ClN~5~O~3~ (461.90): C, 62.41; H, 4.36; N, 15.16%, found: C, 62.40; H, 4.32; N, 15.20%.

4. Conclusions
==============

In summary, the strategy for constructing the target compounds started by 5-aryl-7-hydrazino-2- phenylpyrazolo\[1,5-*c*\]pyrimidines **1a-d** where the hydrazine moiety can be readily heterocyclized with one-carbon inserting agents to give the triazole ring fused to the pyrazolopyrimidine skeleton has been successfully demonstrated.

*Sample Availability:* Samples of compounds **1-11** are available from the author.
